Nippon India Nifty Pharma ETF: Seizes Growth from the Leading Sector - Outside View by PersonalFN

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  

Nippon India Nifty Pharma ETF: Seizes Growth from the Leading Sector
Jun 25, 2021

The Indian Pharmaceutical sector has witnessed a significant growth owing to steady demand and budding sales of drugs and medical supplies amid the COVID-19 pandemic. In terms of pharmaceutical drugs as well as COIVD-19 vaccine production and distribution, the government has taken various measures to support the healthcare and pharmaceutical sector.

India plays an important role in the global pharmaceuticals sector, while the low cost of production boosts the efficiency of Indian pharma companies, which leads to competitive exports. In the Union Budget 2021, the government approved the Production Linked Incentive (PLI) scheme for the benefit of pharmaceutical companies.

The Indian Pharmaceutical sector has been one of the fastest growing sectors. The impact of this second wave and the possibility of a third wave of COVID-19 exhibit a future demand and growth in this sector. An Exchange Traded Fund is a smart way of investing in an entire basket of Pharma stocks rather than selecting individual companies from this leading sector.

--- Advertisement ---
Revealed: A Massive 15x EV Opportunity

We concluded the EV Gold Rush special event yesterday.

And it was a mega success. Thousands of Indians had joined us LIVE.

But for some reason you couldn't make it to the event.

At the event, we revealed our complete research on this massive 15x opportunity in electric vehicles...

Including details of 3 EV stocks that could potentially offer you life-changing gains in the long run.

Click Here to Watch Full Details (Available for a limited time)

Nippon India Mutual Fund has launched Nippon India Nifty Pharma ETF, it is an open-ended scheme replicating/ tracking NIFTY Pharma Index. This scheme offers investors an exposure to leading pharma stocks.

The pharmaceutical sector is evolving and will continue to pursue new opportunities in years to come because of a need to develop better medicine and innovate on healthcare products.

Table 1: Details of Nippon India Nifty Pharma ETF

Type An open-ended scheme replicating/ tracking NIFTY Pharma Index. Category Exchange Traded Fund
Investment Objective The investment objective of the scheme is to provide investment returns closely corresponding to the total returns of the securities as represented by the NIFTY Pharma Index before expenses, subject to tracking errors. However, there can be no assurance or guarantee that the investment objective of the Scheme will be achieved.
Min. Investment Rs 1000/- and in multiples of Re 1 thereafter. Face Value Rs 10/- per unit
Entry Load Not Applicable Exit Load Nil
Fund Manager - Mr Mehul Dama Benchmark Index Nifty Pharma TRI
Issue Opens: June 21, 2021 Issue Closes: June 28, 2021
(Source: Scheme Information Document)

What will the Investment strategy for Nippon India Nifty Pharma ETF be?

Nippon India Nifty Pharma ETF is a passively managed exchange traded fund that will employ an investment approach designed to track the performance of NIFTY Pharma TRI.

The scheme offers investors an opportunity to have exposure to stocks of leading pharma companies. The scheme aims to achieve its objective by investing in securities constituting the NIFTY Pharma Index in the same proportion as in the Index.

It will endeavour to replicate the performance of the underlying index to generate equivalent returns by minimizing tracking errors.

--- Advertisement ---
[Alert] Sell These 3 Stocks Immediately

These 3 stocks are ticking time bombs in your portfolio.

It is very likely that you could be owning these 3 overvalued...

fundamentally weak... ready to crash stocks... in your portfolio today.

Because many stock brokers have painted rosy pictures of these stocks. But the reality is starkly different.

If the market crashes, then these stocks could wipe out your wealth.

You should get rid of these stocks as soon as possible.

Click her for full details of these 3 landmines

About the benchmark

NIFTY Pharma Index captures the performance of the pharmaceutical sector. The Index comprises of 10 companies listed on National Stock Exchange of India (NSE).

NIFTY Pharma Index is computed using the free float market capitalization method, wherein the level of the index reflects the total free float market value of all the stocks in the index relative to a particular base-market capitalization value.

The following list is the top constituents under the index by their weightage as of May 31, 2021:

This scheme, apart from investing 95% of its assets in securities constituting NIFTY Pharma Index, will invest up to 5% of its assets in money market instruments including tri-party repo on government securities or treasury bills, cash & cash equivalents or liquid schemes in order to meet the liquidity requirements of this scheme.

Under normal circumstances, asset allocation will be as under:

Table 2: Asset Allocation of Nippon India Nifty Pharma ETF

Instruments Indicative Allocations
(% of Net Assets)
Risk Profile
Minimum Maximum
Securities constituting NIFTY Pharma Index 95 100 Medium to High
Money Market Instruments including Tri-Party Repo on Government securities or Treasury bills, cash & cash equivalents or Liquid Schemes* 0 5 Low to Medium

*The Fund Manager may invest in Liquid Schemes of Nippon India Mutual Fund and other schemes of a mutual fund registered with SEBI that invest predominantly in the money market securities.

(Source: Scheme Information Document)

Who will manage Nippon India Nifty Pharma ETF?

Mr Mehul Dama will be the dedicated fund manager for this scheme.

Mr Mehul Dama is Fund Manager and Dealer - ETF at Nippon Life India Asset Management Pvt. Ltd. He has over 10 years of experience in financial services. Prior to this, he worked with NAM India as Dealer - ETF and Lead - Finance ETF, Goldman Sachs Asset Management (India) Private Limited as Vice President - Controllers, Benchmark Asset Management Company Private Limited as Assistant Vice President - Operations / Controllers, and Lovelock & Lewes as Assistant Manager.

Mr Dama is Chartered Accountant (C.A) and graduate. The other schemes he manages are Nippon India ETF Consumption, Nippon India ETF Dividend Opportunities, Nippon India ETF Gold BeES, Nippon India ETF Infra BeES, Nippon India ETF Nifty 100, Nippon India ETF NV20, Nippon India ETF PSU Bank BeES, Nippon India ETF Sensex, Nippon India ETF Shariah BeES,

Nippon India Index Fund - Nifty Plan, Nippon India Index Fund - Sensex Plan, Nippon India Gold Savings Fund, Nippon India ETF Nifty Midcap 150, Nippon India Junior BeES FoF, Nippon India ETF Sensex Next 50, Nippon India ETF Nifty IT, Nippon India Nifty Smallcap 250 Index Fund, Nippon India Nifty Midcap 150 Index Fund, Nippon India Nifty 50 Value 20 Index Fund, Nippon India Passive Flexicap FoF.

Fund Outlook - Nippon India Nifty Pharma ETF

Nippon India Nifty Pharma ETF aims to invest in the top 10 Pharma companies listed on NSE and comprise under the Nifty Pharma Index. The scheme's performance will depend on the performance of the underlying index and its constituents.

Pharma has emerged as one of the fastest growing sectors amid the pandemic. However, the sustainability of the growth in this sector will depend on how the companies attain self-sufficiency in manufacturing, accelerate research and innovation, etc. among other factors. If the sector moves out of favour, investment in pharma-oriented funds can lead to heavy losses due to the concentrated nature of the portfolio.

This scheme is simply suitable for investors seeking long-term capital growth and to invest in the scheme replicating the composition of the Nifty Pharma Index. Ensure you have a very high-risk appetite, long investment horizon, and that your investment objective is aligned with the fund.

PS: If you wish to select worthy mutual fund schemes, I recommend that you subscribe to PersonalFN's unbiased premium research service, FundSelect.

Additionally as a bonus, you get access to PersonalFN's popular debt mutual fund service, DebtSelect.

PersonalFN recommendations go through our stringent process that assesses both quantitative and qualitative parameters, providing you with Buy, Hold, and Sell recommendations on equity and debt mutual fund schemes. Read here for details...

Author: Mitali Dhoke

This article first appeared on PersonalFN here.

Join Now: PersonalFN is now on Telegram. Join FREE Today to get 'Daily Wealth Letter' and Exclusive Updates on Mutual Funds

PersonalFN is a Mumbai based personal finance firm offering Financial Planning and Mutual Fund Research services.


The views mentioned above are of the author only. Data and charts, if used, in the article have been sourced from available information and have not been authenticated by any statutory authority. The author and Equitymaster do not claim it to be accurate nor accept any responsibility for the same. The views constitute only the opinions and do not constitute any guidelines or recommendation on any course of action to be followed by the reader. Please read the detailed Terms of Use of the web site.

Equitymaster requests your view! Post a comment on "Nippon India Nifty Pharma ETF: Seizes Growth from the Leading Sector". Click here!


More Views on News

India's Big PSU Selloff: Watch Out for these Top Stocks (Views On News)

Oct 15, 2021

The government's plan to divest its stakes in PSUs could spark off a rally in these four stocks.

Modi's Big Move Could Boost these 5 Defence Stocks (Views On News)

Oct 11, 2021

To corporatise the defence sector, the Ministry of Defence (MoD) has dissolved the 250-year-old Ordnance Factory Board (OFB).

5 Exciting 'Unlisted' Companies and How to Play Them (Views On News)

Oct 7, 2021

Here's how you can invest in some of the most exciting start-ups of the decade.

The Dollar says the Nifty could Rise (Fast Profits Daily)

Oct 26, 2021

Can the dollar index tell us how the Nifty will move? Yes. Find out in this video...

The EV Revolution is a Gamechanger for this Smallcap Stock (Profit Hunter)

Oct 26, 2021

As the EV transition happens this auto ancillary firm only stands to gain.

More Views on News

Most Popular

5 Green Energy Stocks to Watch as India Readies for a Revolution (Views On News)

Oct 13, 2021

The excitement around green energy stocks has opened up a huge contrarian opportunity in the traditional energy space.

Could HDFC Bank be a Big EV Winner? The Answer Will Surprise You... (Profit Hunter)

Oct 13, 2021

Why should investors take it for granted that India's Tesla will be one of the major auto stocks?

Tata Group Stocks are on Fire: Which one Should You Buy? (Profit Hunter)

Oct 15, 2021

Tata group stocks are on fire. Find out which one deserves your attention.

Massive Surge in the Shares of Tata Motors Today. Key Factors Favouring the Rally (Views On News)

Oct 13, 2021

Tata Motors zooms 23% after report of TPG investing Rs 75 bn in EV arm.

India's Big PSU Selloff: Watch Out for these Top Stocks (Views On News)

Oct 15, 2021

The government's plan to divest its stakes in PSUs could spark off a rally in these four stocks.


Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms


Oct 26, 2021 (Close)